Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics by B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

Subjects: Get full text

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal by Xinya Li, Zaiwei Song, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang, Rongsheng Zhao

Subjects: “…Immune checkpoint inhibitors…”
Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: “…immune checkpoint inhibitor…”
Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

Subjects: “…Checkpoint inhibitors…”
Get full text

Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Populat... by Wang RH, Chen Y, Lou YL, Lu YL, Xu HM

Subjects: “…immune checkpoint inhibitors…”
Get full text

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity by Miro Saarela, Essi Parviainen, Ana Lleo, Luca di Tommaso, Hanna Raunio, Krista Kankaanranta, Katri Vuopala, Aino Rönkä, Sini Nurmenniemi, Raija Kallio, Arja Jukkola, Katri S. Selander

Subjects: “…Checkpoint inhibitors…”
Get full text

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study by Ping Zhou, Bing Liu, Ning Shen, Xiaoting Fan, Shangwei Lu, Zhijuan Kong, Ying Gao, Zhimei Lv, Rong Wang

Subjects: Get full text

Autoimmune pancerebellitis as an immune-related adverse event: an illustrative case by D. Valančius, I. Zagorskienė, A. Klimašauskienė

Subjects: “…immune checkpoint inhibitors…”
Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association by Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi

Subjects: “…Immune checkpoint inhibitors…”
Get full text

Resistance mechanisms to immune checkpoint inhibitors: updated insights by Besan H. Alsaafeen, Bassam R. Ali, Eyad Elkord

Subjects: “…Immune checkpoint inhibitors…”
Get full text

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database by Alexandre O. Gérard, Alexandre O. Gérard, Alexandre O. Gérard, Diane Merino, Diane Merino, Jonathan Benzaquen, Alexandre Destere, Delphine Borchiellini, Clément Gosset, Clément Gosset, Fanny Rocher, Marine Andreani, Charles-Hugo Marquette, Henri Montaudié, Henri Montaudié, Milou-Daniel Drici, Antoine Sicard, Antoine Sicard

Subjects: “…immune checkpoint inhibitors…”
Get full text

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable by Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting syste... by Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao, Hanping Wang

Subjects: “…Immune checkpoint inhibitors…”
Get full text

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis by Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Renate Pichler, Jeremy Yuen-Chun Teoh, Marco Moschini, Wojciech Krajewski, Jun Miki, Shahrokh F. Shariat, Takahiro Kimura, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)

Subjects: Get full text

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations by Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan

Subjects: Get full text

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report by Ming-xing Wang, Ai-xin Liu, Qing-ming Sun, Wan-hui Dong

Subjects: Get full text

Progress in immunotherapy for brain metastatic melanoma by Shicheng Zheng, Zhongqiao Lin, Ruibo Zhang, Zihang Cheng, Kaixin Li, Chenkai Gu, Yu Chen, Yu Chen, Jing Lin, Jing Lin

Subjects: Get full text